CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 255 enrolled
Drug / intervention
HSK3486 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04711837
NCT04711837Phase 3Completed

A Multicenter, Randomized, Double-blinded, Propofol-controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of HSK3486 Injectable Emulsion for Induction of General Anesthesia in Adults Undergoing Elective Surgery.

Haisco-USA Pharmaceuticals, Inc.·interventional·Posted Jan 15, 2021·Updated Oct 10, 2025

In Brief

A Phase 3 clinical trial evaluating HSK3486 and Propofol for Anesthesia. Completed, enrolled 255 participants across 13 sites.

Detailed Summary

This is a multicenter, randomized, double-blinded, propofol-controlled, Phase 3 clinical study to evaluate the efficacy and safety of HSK3486 for induction of general anesthesia in adults undergoing elective surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnesthesia
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedJan 15, 2021
Enrollment StartFeb 11, 2021
Primary CompletionApr 13, 2022
Study CompletionApr 20, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 5.5 years ago

Interventions

HSK3486drug

HSK3486 for induction of general anesthesia.

Propofoldrug

Propofol for induction of general anesthesia.